blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3107530

EP3107530 - PHARMACEUTICAL COMPOSITION COMPRISING APIXABAN [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  06.04.2018
Database last updated on 30.07.2024
FormerExamination is in progress
Status updated on  23.02.2018
FormerRequest for examination was made
Status updated on  25.11.2016
Most recent event   Tooltip06.04.2018Withdrawal of applicationpublished on 09.05.2018  [2018/19]
Applicant(s)For all designated states
Sandoz AG
Lichtstrasse 35
4056 Basel / CH
[2016/52]
Inventor(s)01 / STANIC LJUBIN, Tijana
c/o Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
02 / BERGLEZ, Sandra
c/o Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
03 / NOVAK STAGOJ, Mateja
c/o Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
04 / PERHAVEC, Petra
c/o Lek Pharmaceuticals d.d.
Verovskova 57
1526 Ljubljana / SI
 [2016/52]
Representative(s)Prüfer & Partner mbB Patentanwälte · Rechtsanwälte
Sohnckestraße 12
81479 München / DE
[2016/52]
Application number, filing date15705016.216.02.2015
[2016/52]
WO2015EP53224
Priority number, dateEP2014015546617.02.2014         Original published format: EP 14155466
[2016/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015121472
Date:20.08.2015
Language:EN
[2015/33]
Type: A1 Application with search report 
No.:EP3107530
Date:28.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 20.08.2015 takes the place of the publication of the European patent application.
[2016/52]
Search report(s)International search report - published on:EP20.08.2015
ClassificationIPC:A61K9/20, A61K31/4545
[2016/52]
CPC:
A61K31/4545 (EP,US); A61K9/2013 (EP,US); A61K9/2027 (EP,US);
A61K9/2031 (EP,US); A61K9/2054 (EP,US); A61K9/2095 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/52]
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT APIXABAN[2016/52]
English:PHARMACEUTICAL COMPOSITION COMPRISING APIXABAN[2016/52]
French:COMPOSITION PHARMACEUTIQUE CONTENANT DE L'APIXABAN[2016/52]
Entry into regional phase14.09.2016National basic fee paid 
14.09.2016Designation fee(s) paid 
14.09.2016Examination fee paid 
Examination procedure14.09.2016Examination requested  [2016/52]
14.09.2016Date on which the examining division has become responsible
21.03.2017Amendment by applicant (claims and/or description)
23.02.2018Despatch of a communication from the examining division (Time limit: M04)
29.03.2018Application withdrawn by applicant  [2018/19]
Fees paidRenewal fee
10.02.2017Renewal fee patent year 03
14.02.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]EP2554159  (RATIOPHARM GMBH [DE]) [X] 1-6,9,11-15 * paragraph [0001] * * paragraph [0007] - paragraph [0015] * * paragraph [0052] - paragraph [0058] * * paragraph [0099] - paragraph [0109] * * examples 1,4 * [I] 7,8,10;
 [XD]WO2011106478  (SQUIBB BRISTOL MYERS CO [US], et al) [XD] 1-4,11-15 * paragraph [0001] * * paragraph [0005] - paragraph [0006] * * paragraph [0022] - paragraph [0024] * * tables 3-6 * * claims 1,13,16,17 *;
 [X]WO2010147978  (PFIZER [US], et al) [X] 1-4,6,11-15 * page 1, line 4 - line 7 * * examples 6,7 *
 [A]  - ROWE R C ET AL, POLYVINYL ALCOHOL, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, PHARMACEUTICAL PRESS [U.A.], GB, PAGE(S) 592 - 593, (20060101), ISBN 978-1-58212-058-4, XP003015000 [A] 1-15 * table 1 *
 [A]  - ROWE R C ET AL, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, HYDROXYPROPYL CELLULOSE, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, LONDON : PHARMACEUTICAL PRESS, GB, PAGE(S) 289 - 293, (20030101), ISBN 978-1-58212-022-5, XP001562204 [A] 1-15 * the whole document * * paragraph [0007] * * tables 3,5 *
 [A]  - Anonymous, "Kollicoat IR", Internet citation, (20130201), pages 1 - 14, URL: http://www.pharma-ingredients.basf.com/Statements/Technical Informations/EN/Pharma Solutions/03_030724e_Kollicoat IR.pdf, (20140703), XP055126802 [A] 1-15 * the whole document * * paragraph 3.1 "Applications" * * paragraph 4.3 "Wet binding - Acetaminophen instant granules" *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.